• Circular RNA CAR-T for DLL3-Positive SCLC

  2026-10-05

  Cai et al. evaluated a transient, circular RNA-encoded DLL3 CAR-T strategy for small cell lung cancer and reported stronger antitumor activity than an mRNA-based comparator in cell and mouse models. The findings support circRNA as a preclinical platform for temporary CAR expression, while leaving important questions about clinical safety, manufacturing, durability, and tumor heterogeneity unresolved.

• Protease Inhibitor Cocktail EDTA-Free: Product Overview

  2026-10-05

  APExBIO’s SKU K1010 is an EDTA-free protease inhibitor mixture supplied as a 100X concentrate in DMSO. The available evidence is limited to supplier-described identity and conceptual scope; no matched paper evidence or independent performance validation is available.

• Berberine, RXRα/PPARγ, and SASP in Atherosclerosis

  2026-10-04

  A 2025 study identifies an RXRα/PPARγ/NEDD4 signaling axis through which berberine suppresses senescence-associated secretory phenotype inflammation in macrophage-derived foam cells and atherosclerotic plaques. The work connects nuclear-receptor activation with ubiquitin-mediated regulation of the GATA4/p62 complex, while its mouse and cellular evidence supports further mechanistic investigation rather than immediate clinical translation.

• T0070907: Stress-Testing PPARγ Signaling

  2026-10-03

  A translational perspective on T0070907 as a mechanistically informative PPARγ antagonist, using the RXRα/PPARγ/NEDD4 findings in berberine-treated atherosclerosis to define testable questions, evidence boundaries, and future research opportunities.

• Chronic Cabozantinib Remodeling in RCC

  2026-10-01

  A 2026 phosphoproteomic study distinguishes acute from chronic cabozantinib adaptation in renal cell carcinoma, showing that prolonged exposure preserves suppression of activating MET phosphorylation while redirecting signaling toward adhesion-, stress-, and MAPK/AP-1-associated programs. The findings provide a useful framework for interpreting motility assays and designing experiments that separate immediate drug responses from long-term cellular adaptation.

• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-10-01

  Wang et al. identify a METTL16–SENP3–LTF signaling axis that links m6A RNA regulation, protein SUMOylation, iron handling, and ferroptosis resistance in hepatocellular carcinoma. The study provides a multi-model framework for investigating how altered iron availability supports HCC progression and for evaluating strategies that may restore ferroptotic sensitivity.

• Protoporphyrin IX Workflows for Heme & Photodynamic Assays

  2026-10-01

  Build more reliable heme-biosynthesis, photodynamic, and ferroptosis-adjacent assays with a workflow that treats solubility, light exposure, and iron biology as separate experimental variables. The guide connects Protoporphyrin IX use to the METTL16-SENP3-LTF findings in hepatocellular carcinoma while clearly separating validated evidence from practical pilot conditions.

• Berberine Targets RXRα/PPARγ/NEDD4 in Atherosclerosis

  2026-09-30

  This 2025 study identifies an RXRα/PPARγ/NEDD4 signaling axis through which berberine suppresses SASP-related inflammation in macrophage-derived foam cells and ApoE−/− atherosclerosis models. Its combination of Smart-seq profiling, molecular validation, and macrophage-specific RXRα knockdown provides a mechanistic framework for studying how nuclear-receptor activity controls inflammatory aging in plaques.

• Spiroplasma Entry into S2 Cells and Endocytosis

  2026-09-29

  Wei et al. established a Drosophila Schneider 2 cell model to show that Spiroplasma eriocheiris invades insect cells, proliferates intracellularly, and causes substantial cellular injury. Pharmacological and cytoskeletal perturbation experiments implicate clathrin-mediated endocytosis and macropinocytosis, providing a mechanistic framework for studying this crustacean pathogen in an invertebrate cellular system.

• B. fragilis and Gut-Brain Cholinergic Seizure Control

  2026-09-29

  Jia et al. identify a gut–vagus–brain cholinergic circuit through which Bacteroides fragilis suppresses seizures in mouse models and improves outcomes in a pediatric refractory epilepsy trial. The study connects colonic ChAT-positive cells, vagal signaling, and intestinal Lactobacillus enrichment, providing a mechanistic framework for microbiota-targeted antiseizure research.

• Oltipraz Workflows for Nrf2 Liver Research

  2026-09-28

  Oltipraz provides a defined small-molecule way to interrogate Nrf2-driven phase II enzyme induction in liver and MASLD-related models. This workflow pairs concentration-controlled Nrf2 assays with autophagy and ferroptosis readouts inspired by recent Qushi Huoxue ointment research, while preserving clear limits on what can be attributed to a single compound.

• How Isochlorogenic Acid A Disrupts HBV Replication

  2026-09-28

  A study in Antiviral Research finds that isochlorogenic acid A affects several stages of the hepatitis B virus life cycle, including viral gene expression, genome maintenance, and particle assembly. Its effects are associated with HO-1 upregulation and altered intracellular reactive oxygen species, suggesting a host redox pathway worth investigating while leaving the exact causal steps to be resolved.

• 1,2-Dioleoyl-sn-glycero-3-PE (DOPE) Workflow

  2026-09-27

  DOPE is a helper phospholipid for researchers building cationic liposomes and other lipid formulations for nucleic acid delivery, where it may support endosomal membrane fusion and cytoplasmic release. It is not water-soluble and should not be treated as a stand-alone aqueous transfection reagent; prepare it in a compatible organic solvent and evaluate it within the complete formulation.

• Ribonuclease R (RNase R) (20 U/μL) Workflows

  2026-09-26

  Learn how RNase R can support circular RNA enrichment and interpretation of cell-based cancer studies without confusing RNA analysis with direct viability measurement. This practical guide covers controls, workflow limits, and product-selection considerations for SKU K3061.

• Spiroplasma Entry into S2 Cells: Two Uptake Routes

  2026-09-25

  Wei and colleagues established a Drosophila Schneider 2 (S2) cell model and found that Spiroplasma eriocheiris entry depends on clathrin-mediated endocytosis and macropinocytosis, with cytoskeletal components also contributing. The inhibitor-based evidence offers a framework for studying bacterial uptake in an invertebrate cell model, while requiring careful interpretation because pharmacological perturbations do not identify a single molecular target by themselves.

8033 records 1/536 page Next 12345 下5页 Last page